LAMIVUDINE

Pre-Launch

lamivudine

ANDAORALTABLET
Lifecycle
Pre-Launch
Clinical Trials
20

Clinical Trials (5)

NCT06811246Phase 1Completed

A Clinical Study of Islatravir and Its Interaction With Lamivudine (MK-8591-058)

Started Feb 2024
20 enrolled
Healthy
NCT04453436N/AActive Not Recruiting

HIV Drug Resistance Among Individuals Failing Tenofovir/Lamivudine and Dolutegravir First Line Regimen in Brazil

Started Sep 2023
2,500 enrolled
HIVDrugResistance
NCT04665375Phase 4Terminated

Can INSTI-associated Weight Gain be Halted or Reversed With a Switch to Doravirine/Lamivudine/Tenofovir DF?

Started Apr 2021
HivWeight Gain
NCT04021290Phase 3Completed

Regimen Switch to Dolutegravir/Lamivudine Fixed Dose Combination From Current Antiretroviral Regimen in HIV-1 Infected and Virologically Suppressed Adults (SALSA)

Started Nov 2019
493 enrolled
HIV Infections
NCT03685500Phase 4Completed

A Clinical Trial to Evaluate the Reversibility of Abacavir/Lamivudine/Dolutegravir CNS-Related Neurotoxicity After Switching to Tenofovir/Alafenamide/Emtricitabine/Darunavir/Cobicistat (TAF/FTC/DRV/c)

Started Dec 2018
78 enrolled
HIV Infections